Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO) shares hit a new 52-week low on Thursday . The company traded as low as C$0.50 and last traded at C$0.50, with a volume of 1500 shares trading hands. The stock had previously closed at C$0.49.
Aptose Biosciences Stock Performance
The firm has a market capitalization of C$9.06 million, a PE ratio of -0.08 and a beta of 1.36. The company has a current ratio of 0.80, a quick ratio of 5.41 and a debt-to-equity ratio of 670.80. The business’s 50 day simple moving average is C$0.55 and its two-hundred day simple moving average is C$1.07.
Aptose Biosciences (TSE:APS – Get Free Report) (NASDAQ:APTO) last announced its earnings results on Thursday, August 8th. The biotechnology company reported C($0.59) earnings per share for the quarter, beating analysts’ consensus estimates of C($0.80) by C$0.21. Research analysts expect that Aptose Biosciences Inc. will post -0.59 earnings per share for the current fiscal year.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
See Also
- Five stocks we like better than Aptose Biosciences
- What is the S&P 500 and How It is Distinct from Other Indexes
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- How to Invest in Small Cap Stocks
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
